Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients with Parkinson’s Disease

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512532-30-00

Acronym

14-XC-CL

Enrollment

Registered

2024-09-03

Start date

2024-09-18

Completion date

2025-08-14

Last updated

2024-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s Disease

None listed

Sex/Gender

All

Age

18 Years to No maximum

Finland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026